What changed for Lung Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Lung Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 30 to 31 (+1)
- Trials recruiting worldwide 867 to 886 (+19)
- Late-stage (Phase 3) trials 94 to 96 (+2)
- Trials on record 4,788 to 4,937 (+149)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Lung Cancer in July 2026. Voxsanity tracks 22 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 156 trials tracked for Lung Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04655976 · results posted 1 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04655976) enrolled 758 people across three groups. Participants in Arm A (305 people) received a combination of three medicines — cobolimab, dostarlimab, and docetaxel. Arm B (301 people) received dostarlimab and docetaxel. Arm C (152 people) received docetaxel alone, serving as the comparison group. The trial was primarily measuring overall survival — that is, how long, on average, participants lived from the time they joined the study. The reported data shows that the median overall survival (the point at which half of...
-
NCT06145048 · results posted 13 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 89 adults who were scheduled for lung surgery. All 89 participants received a single intravenous (into the vein) dose of an investigational imaging agent called VGT-309, given 12 to 36 hours before their operation. The trial was measuring how often this agent — which is designed to make certain tissue glow under a special near-infrared (NIR) light during surgery — provided information that standard surgical methods alone did not. Eighty-eight participants completed the study, and one did not. The reported data shows...
-
NCT06380361 · results posted 21 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people, all placed into a single group. The trial was testing a device called the BioSpy System, which takes electrical measurements of tissue during a bronchoscopy (a procedure where a thin tube is passed into the airways to examine the lungs). The main goal was to see whether the device could successfully record these electrical measurements from suspicious tissue areas. Three participants did not complete the trial, leaving 27 who finished. The reported data shows that for the primary goal — successfully obtain...
-
NCT04222972 · results posted 5 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04222972) enrolled 223 participants across two main treatment groups during the treatment period: 113 people received standard-of-care (SOC) treatment and 110 received a medicine called pralsetinib. A further 38 participants later crossed over to receive pralsetinib in a separate crossover period. The trial was primarily measuring how long participants lived without their cancer growing or spreading — a measure called "progression-free survival" — and also looked at a range of other outcomes including how many participants...
-
NCT05388669 · results posted 2 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05388669) enrolled 418 people in total — 206 in one group who received a medicine called lazertinib together with amivantamab given as an injection under the skin (called SC-CF), and 212 in a second group who received lazertinib together with amivantamab given through a drip into a vein (called intravenous or IV). The trial was primarily measuring how much of the amivantamab medicine was present in participants' blood — specifically the amount remaining just before the next dose was due (called the "trough concentration")...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05740566 · results posted 5 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05740566) enrolled 509 people with small cell lung cancer. Participants were split into two groups: 255 received standard of care treatment, and 254 received an investigational medicine called tarlatamab (given at doses ranging from 1 mg to 10 mg, every two weeks). The trial was set up to measure several things, including how long participants went without their disease getting worse (called progression-free survival), how their quality of life changed over time, and whether their tumours shrank or stopped growing. The re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04916002 · results posted 5 December 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two medicines — CMP-001 and cemiplimab — in people with certain types of advanced skin cancer. The trial included 77 participants in total, spread across five groups: two groups with cutaneous squamous cell carcinoma (CSCC, a common type of skin cancer), two groups with Merkel cell carcinoma (MCC, a rarer skin cancer), and one group with basal cell carcinoma (BCC, another type of skin cancer). The trial was measuring how often tumours shrank or disappeared, how long any response lasted, and how long...
-
NCT03132532 · results posted 25 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03132532) enrolled 20 people in total — 10 in each group. Both groups received platinum-based chemotherapy (a common type of cancer drug given as a drip) alongside a form of radiation therapy called proton beam therapy (PBT). One group received a lower radiation dose and the other received a higher radiation dose. The trial was measuring how long participants went without their disease getting worse (called progression-free survival), as well as a number of other things including how long participants lived overall, whethe...
-
NCT03334617 · results posted 27 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03334617) enrolled a total of 632 participants across 22 different treatment groups. It was a multi-part study testing several different drug combinations — all involving the immunotherapy drug durvalumab paired with one of a number of other investigational medicines — in people with cancer. The trial was divided into separate "modules," each testing a different drug combination in participants who were grouped based on features of their cancer. The main thing the trial set out to measure was how many participants had thei...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05513703 · results posted 24 October 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called telisotuzumab vedotin in 9 participants. All 9 received at least one dose of the study drug, and none were recorded as having completed the study — all 9 were listed as "not completed," though the reasons for this are not detailed in the data provided. The trial's main goal was to measure the **objective response rate** — that is, the proportion of participants whose tumours showed a confirmed meaningful shrinkage (either a complete or partial response) as judged by an independent review team. The repo...
-
NCT04256421 · results posted 22 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04256421) enrolled 490 people in total — 247 in the group receiving a placebo plus atezolizumab (Arm A), and 243 in the group receiving tiragolumab plus atezolizumab (Arm B). The trial was measuring several things: how long participants went without their disease getting worse (progression-free survival, or PFS), how long they lived overall (overall survival, or OS), what proportion of participants saw their tumour shrink or disappear (objective response rate, or ORR), and how long those responses lasted (duration of respo...
-
NCT03307759 · results posted 15 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 people in total — 5 in one group who received radiation therapy (called SABR) followed by an immunotherapy drug called pembrolizumab, and 8 in a second group who received pembrolizumab first and then the radiation therapy. The trial was investigating the order in which these two treatments were given, and was primarily looking at serious side effects. It also measured how tumours responded to treatment and how many participants were still alive at around two years. The reported data shows that when it came to seri...
-
NCT02819024 · results posted 22 August 2025
According to the results reported on ClinicalTrials.gov, six people took part in this trial, and five completed it (one did not finish). All participants were in a single group that received dexamethasone (a steroid medicine) and underwent a type of specialised scan called an 18F-FLT PET scan. This scan measures how quickly cells in a tumour are dividing and growing. The trial was looking at whether this type of scan could detect changes in tumour activity after treatment, and also at changes in certain biological markers in the blood linked to a process called cellular senescence (a state whe...
-
NCT04579679 · results posted 25 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 78 people in total across four groups, all of whom had a type of tumour called a neuroendocrine tumour (NET) originating from different parts of the body: the lung (20 people, Cohort A), the small bowel (32 people, Cohort B), other locations (20 people, Cohort C), and a mixed "any NET" group (6 people, Cohort D). The trial was measuring how participants' tumours responded to a medicine called surufatinib, looking mainly at whether tumours shrank, stayed stable, or continued to grow. The reported data shows that the p...
-
NCT04026412 · results posted 24 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04026412) enrolled 925 people across three treatment groups. Arm A (287 people) received nivolumab combined with a type of radiation-plus-chemotherapy treatment, followed by nivolumab and ipilimumab. Arm B (320 people) received the same starting treatment followed by nivolumab alone. Arm C (318 people) received the radiation-plus-chemotherapy treatment followed by durvalumab. The trial was primarily measuring how long participants went without their disease getting worse — known as "progression-free survival" — comparing A...
-
NCT04656652 · results posted 23 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04656652) enrolled 604 people with lung cancer — 299 received a treatment called DS-1062a (also known as datopotamab deruxtecan) at a dose of 6.0 mg/kg, and 305 received a standard chemotherapy called docetaxel. The trial was measuring two main things: how long participants went without their cancer getting worse (called progression-free survival), and how long participants lived overall (called overall survival). A smaller number of participants in each group completed the full study period — 68 in the DS-1062a group and...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04921358 · results posted 29 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 377 people with a type of lung cancer who had already received prior treatment. Participants were randomly assigned to receive either a combination of two medicines — tislelizumab and sitravatinib — or a standard chemotherapy medicine called docetaxel. The trial was measuring how long people lived overall, how long they lived before their disease got worse, and how many people's disease responded to or was controlled by treatment. The reported data shows that for overall survival (how long participants lived from the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06094296 · results posted 16 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06094296) was designed to test a combination of medicines — BMS-986315, nivolumab, and chemotherapy chosen based on tumour type — across two planned parts and multiple treatment groups. The trial was set up to enrol participants across four groups. However, the reported data shows that only **one person** was enrolled in total, placed in the first group (Part 1), and that person did not complete the study. No participants were enrolled in the other three groups (Part 2 Arms A, B, or C). The reported outcome numbers from P...
-
NCT01853826 · results posted 11 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01853826) enrolled 481 participants, all of whom were in a single group receiving the drug afatinib. Of those, 479 actually received the treatment. The trial was primarily measuring how many participants experienced unwanted or unexpected health events (called adverse events) while taking afatinib, using a standard medical checklist known as CTCAE version 3.0 — a common tool used to record and grade these kinds of events in clinical trials. The reported data shows that out of the 479 participants who received afatinib, 47...
-
NCT04786964 · results posted 2 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04786964) enrolled 25 people in total — 19 in the Cosibelimab group and 6 in the Control group. All 25 participants completed the study period. The trial was designed to measure several things related to a cancer treatment: how long participants lived overall, how long they lived without their disease getting worse, how many showed a measurable reduction in their cancer, how long any such reduction lasted, and how many participants experienced any unwanted medical events (called adverse events) during the study. The repor...
-
NCT05834348 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05834348) enrolled a total of 5,279 people with a type of lung cancer called non-small cell lung cancer (NSCLC). Participants were split into two groups: 618 people in the "Biomarker Cohort" — meaning their tumours were tested for specific genetic markers (EGFR, ALK, or ROS1) — and 4,661 people in the "Non-biomarker Cohort," whose tumours did not have those markers identified. The trial was observational, meaning it tracked real-world treatment patterns and outcomes rather than testing a new drug, looking at how long peopl...
-
NCT02486718 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02486718) involved people who had been treated for non-small cell lung cancer (NSCLC) that had been surgically removed. The trial had two phases: first, 1,280 people were enrolled and assessed, with 1,005 completing that initial phase. Then, 1,005 of those participants were randomly assigned to receive either atezolizumab (507 people) or best supportive care — meaning standard monitoring and symptom management without additional cancer treatment (498 people). The trial was primarily measuring "disease-free survival" (DFS),...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04495894 · results posted 4 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04495894) looked at giving a pain-relief medicine called ketorolac before surgery to people with one of two types of cancer — non-small cell lung cancer (NSCLC) or kidney cancer (renal cell carcinoma, RCC). In total, 68 people started the trial across four groups: those with lung cancer who received ketorolac (16 people) or did not (6 people), and those with kidney cancer who received ketorolac (33 people) or did not (13 people). After some participants dropped out before completing the study activities, the final numbers...
-
NCT03976323 · results posted 6 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03976323) enrolled 1,003 people in an initial "induction phase," where everyone received a combination of pembrolizumab, pemetrexed, and platinum-based chemotherapy. Of those, 672 completed that phase. Then, 672 participants who responded well enough moved into a "maintenance phase," where they were split into two groups: 337 people received pembrolizumab plus olaparib, and 335 received pembrolizumab plus pemetrexed. The trial was measuring two main things — how long people went without their cancer growing (called progres...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05089734 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05089734) enrolled 299 people in the Sacituzumab Govitecan (SG) group and 304 people in the Docetaxel group — 603 participants in total. The trial was comparing these two treatments in people with a type of lung cancer, measuring how long participants lived overall, how long it took for their disease to progress, and how many showed a measurable reduction in their tumours. The reported data shows that for overall survival — the time from joining the trial until death from any cause — the median figure (meaning half of par...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01463423 · results posted 19 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 256 people with lung cancer across three groups: 84 people with early-stage (limited) non-small cell lung cancer (NSCLC), 87 people with a history of NSCLC, and 85 people with advanced or spread (metastatic) lung cancer. The trial was measuring how well a precisely targeted form of radiation treatment called Stereotactic Ablative Radiotherapy (SABR) could keep tumours under control, and also tracked side effects and survival over time. The reported data shows that for the primary measure — the number of tumour lesion...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03523702 · results posted 3 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03523702) enrolled 25 people, all of whom completed the study. Participants had a type of lung cancer called locally advanced non-small cell lung cancer (NSCLC) and a high level of a protein marker called PD-L1 (at least 50%). The trial looked at what happened to participants after they received a sequence of two treatments — a medicine called pembrolizumab followed by radiotherapy (targeted radiation). The main thing researchers were tracking was how many participants went 12 months without their cancer getting worse (cal...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05171777 · results posted 21 November 2024
According to the results reported on ClinicalTrials.gov, this trial looked at whether people receiving a cancer treatment called atezolizumab preferred getting it as a subcutaneous (SC) injection — a short jab under the skin — or as an intravenous (IV) infusion, which is delivered through a drip into a vein and takes longer. The trial enrolled participants in two main phases: a "crossover" phase, where 89 and 90 people (in two groups) each tried both the injection and the drip in different orders, and a "continuation" phase involving a separate group of 26 people on IV and 89 on SC. Participan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04866017 · results posted 31 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04866017) enrolled 63 people across three groups. Twenty-two participants received a combination of two immunotherapy medicines — ociperlimab and tislelizumab — alongside a standard radiation-and-chemotherapy treatment (called concurrent chemoradiotherapy, or cCRT). Nineteen participants received tislelizumab plus cCRT, and 22 received cCRT followed by a different immunotherapy medicine called durvalumab. The trial was set up to measure how long people went without their cancer growing or spreading (called progression-free...
-
NCT04889989 · results posted 15 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04889989) enrolled 13 participants who underwent a procedure called microwave ablation — a technique that uses heat generated by microwaves to target tumours in the lung. The trial was measuring how completely the ablation procedure covered the tumours, as well as tracking things like whether tumours came back at the treated site and how many participants were still alive one year later. Of the 13 who started, 6 completed the full study, while the remaining 7 did not complete it for various reasons including 1 who withdrew...
See all 156 reported results for Lung Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, lung cancer currently attracts a very large amount of public research funding from the United States, and that investment has remained broadly steady over recent years. This level of sustained commitment suggests that lung cancer continues to be treated as a serious global health priority by major research institutions. For patients, this is an encouraging sign that...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.